Education
About Us
Working with TipRanks
Follow Us
Lineage Cell Therapeutics, Inc. (LCTX)
:LCTX
LCTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.37 - $1.80
Previous CloseN/A
Volume522.43K
Average Volume (3M)1.53M
Market Cap
$408.76M
Enterprise Value$165.80M
Total Cash (Recent Filing)$42.29M
Total Debt (Recent Filing)$2.15M
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Nov 05, 2025EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding228,356,300
10 Day Avg. Volume1,934,175
30 Day Avg. Volume1,532,161
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.41
Enterprise Value/Revenue15.19
Enterprise Value/Gross Profit15.57
Enterprise Value/Ebitda-8.32
Forecast
1Y Price Target
$5.67Price Target Upside235.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Financial PositionThe company ended the period with $42.3M in cash, which is expected to provide runway into 1Q27 and may be extended by additional collaboration agreements or milestones from Roche.
Product DevelopmentLineage Cell Therapeutics announced the initiation of cell transplant therapy program, ILT1, for pancreatic islet cells in Type 1 diabetes.
Strategic PartnershipsLineage announced a research collaboration with William Demant Invest to help fund the advancement of ReSonance through preclinical studies for hearing loss.
Bears Say
Investment RisksThe investment case for Lineage rests significantly on its OpRegen program in collaboration with global partner Roche.
Market CompetitionLineage's cell transplant therapies may create opportunities to out-license specific product candidates with reduced additional spend on design and manufacturing compared to other forms of pharmaceuticals.
Lineage Therap News
LCTX FAQ
What was Lineage Cell Therapeutics, Inc.’s price range in the past 12 months?
Lineage Cell Therapeutics, Inc. lowest stock price was $0.36 and its highest was $1.80 in the past 12 months.
What is Lineage Cell Therapeutics, Inc.’s market cap?
Lineage Cell Therapeutics, Inc.’s market cap is $408.76M.
When is Lineage Cell Therapeutics, Inc.’s upcoming earnings report date?
Lineage Cell Therapeutics, Inc.’s upcoming earnings report date is Nov 05, 2025 which is in 34 days.
How were Lineage Cell Therapeutics, Inc.’s earnings last quarter?
Lineage Cell Therapeutics, Inc. released its earnings results on Aug 12, 2025. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of -$0.027 by -$0.103.
Is Lineage Cell Therapeutics, Inc. overvalued?
According to Wall Street analysts Lineage Cell Therapeutics, Inc.’s price is currently Undervalued.
Does Lineage Cell Therapeutics, Inc. pay dividends?
Lineage Cell Therapeutics, Inc. does not currently pay dividends.
What is Lineage Cell Therapeutics, Inc.’s EPS estimate?
Lineage Cell Therapeutics, Inc.’s EPS estimate is -0.03.
How many shares outstanding does Lineage Cell Therapeutics, Inc. have?
Lineage Cell Therapeutics, Inc. has 228,356,300 shares outstanding.
What happened to Lineage Cell Therapeutics, Inc.’s price movement after its last earnings report?
Lineage Cell Therapeutics, Inc. reported an EPS of -$0.13 in its last earnings report, missing expectations of -$0.027. Following the earnings report the stock price went up 1.98%.
Which hedge fund is a major shareholder of Lineage Cell Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LCTX
Lineage Therap Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.67 (235.50% Upside)
$5.67 (235.50% Upside)
Hedge Fund Trend
Decreased
By 6.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 5.6%
Last 30 Days ▼ 5.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
86.74%
12-Months-Change
Fundamentals
Return on Equity
-70.12%
Trailing 12-Months
Asset Growth
-11.68%
Trailing 12-Months
Company Description
Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
LCTX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook with significant progress in the OpRegen and OPC1 programs, including promising clinical results and strategic partnerships. However, financial challenges, including a substantial impairment expense and warrant liabilities, contributed to a notable net loss.View all LCTX earnings summariesLCTX Stock 12 Month Forecast
Average Price Target
$5.67
▲(235.50% Upside)
Technical Analysis
Cellectis SA
―
Editas Medicine
―
Nkarta
―
Neumora Therapeutics, Inc.
―
Contineum Therapeutics, Inc. Class A
―
Ownership Overview
58.68% Insiders
6.64% Mutual Funds
25.72% Other Institutional Investors
5.76% Public Companies and
Individual Investors